SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: j_fir2 who wrote (3536)8/4/1999 8:07:00 PM
From: Biomaven  Read Replies (2) of 10280
 
j'fir,

As Bruce pointed out, thalidomide is being marketed by Celgene. They are not actually marketing an ICE - just the original version. Although likely only one isomer of thalidomide causes birth defects, the two isomers are converted into each other in the body. This means there is not much point in developing a single isomer version - a great pity, because in many respects thalidomide turns out to be a wonder drug (as long as you are not pregnant, of course).

Although it is currently approved only for a rare complication of leprosy, it likely works well in a number of conditions - multiple myeloma, ulcerative colitis, rheumatoid arthritis and probably many cancers.

Celgene of course also has its own strong ICE play in a chiral version of Ritalin.

If I was SEPR, I would gobble up CELG.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News